ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates

ASH HIGHLIGHTS 2024 ROUNDTABLE DISCUSSIONS
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Julie Bergeron

Icon Chair Speaker

Speaker

Dr. Lynn Savoie

Dr. Brett Houston

Studies / Trials Discussed

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates

Studies/trials discussed:

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates
Tagged